Cell Therapeutics raises $40m from single investor while Novartis mulls Pixuvri
This article was originally published in Scrip
Executive Summary
Cell Therapeutics raised $40 million to commercialize the European launch of Pixuvri (pixantrone) and finance the acquisition of pacritinib from Singapore company S*BIO, from a single undisclosed institutional investor.